Key clinical point: A retrospective study suggests frontline ibrutinib treatment was associated with lower total health care costs, compared with chemoimmunotherapy, in patients with chronic lymphocytic leukemia (CLL).

Major finding: Ibrutinib monotherapy was associated with net monthly cost savings of $3,766, compared with chemoimmunotherapy and bendamustine/rituximab (P less than .0001).

Study details: A claims-based retrospective analysis of 1,161 patients with CLL.

Disclosures: The authors reported financial affiliations with Janssen Scientific Affairs, which funded the study, and other companies.